Kolexia
Cymbalista Florence Médecine générale
Cymbalista Florence
Médecine générale
Hôpital Avicenne
Bobigny, France
253 Activités
323 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie chronique lymphocytaire à cellules B Leucémies Leucémie lymphoïde Lymphomes Maladie résiduelle Hémorragie Fibrillation auriculaire COVID-19 Lymphome à cellules du manteau

Collaborateurs

Voir plus
Leblond Véronique
Leblond Véronique
Hôpital Pitie Salpetriere, Paris, France
Levy Vincent
Levy Vincent
Hôpital Avicenne, Bobigny, France
Letestu Remi
Letestu Remi
Hôpital Avicenne, Bobigny, France
Feugier Pierre
Feugier Pierre
Hôpital Brabois, Vandoeuvre-lès-Nancy, France

Industries

Voir plus
AstraZeneca
29 collaboration(s)
Dernière en 2022
Abbvie
17 collaboration(s)
Dernière en 2023
Janssen
11 collaboration(s)
Dernière en 2022
Edimark
4 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
ElevateTN: A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL
Essai Clinique (Acerta Pharma BV)   29 février 2024
Identification of the Axis β-Catenin-BTK in the Dynamic Adhesion of Chronic Lymphocytic Leukemia Cells to Their Microenvironment.
International journal of molecular sciences   18 décembre 2023
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
65th ASH Annual Meeting Abstracts   02 novembre 2023
Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN
65th ASH Annual Meeting Abstracts   02 novembre 2023
De Paris à Boston, 20 éditions de l’iwCLL… Bilan et perspectives
Edimark   01 octobre 2023
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO): A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)
Essai Clinique (SecuraBio)   07 septembre 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Blood advances   28 juillet 2023
Immuno-regulatory malignant B cells contribute to Chronic Lymphocytic Leukemia progression.
Cancer gene therapy   28 mars 2023
CGPSR: Genomic and Proteomic Study of Richter Syndrome
Essai Clinique (CHU Nancy)   23 mars 2023